Skip to content

Author

Yaxi Du

We have 3 of 24 papers

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Nov 2026

Case Report: Long-term survival of a patient with lung adenocarcinoma harboring EGFR 19del/T790M/C797S and KIF26B-NTRK1 rearrangement

Epidermal growth factor receptor (EGFR) gene mutation stands as one of the most prevalent driver genetic alterations in non-small cell lung cancer (NSCLC). While targeted therapies against EGFR have substantially enhanced patient prognosis, acquired resistance remains a core challenge that limits therapeutic efficacy....

Zhuo-Ying Li, Rui Liu, Jian-Ping Wu et al. · 0 citations
Open access Sep 2026

A Lynch Syndrome Family With Germline MLH1 c.931A>G Showing Preserved Tumor MMR Immunostaining but MSI‐H Status: A Case Report

This case highlights that preserved tumor MMR immunostaining does not exclude Lynch syndrome when clinical suspicion is high and Concurrent MSI and MMR immunohistochemistry, interpreted together with tumor sequencing and germline testing, may improve diagnosis, treatment selection, and familial risk assessment.

Jing-Jing Cai, Zhuo-Ying Li, Ting-Ting Han et al. · 0 citations
Aug 2026

ACOD1 enhances the ferroptosis resistance of tumor-associated macrophages through the KEAP1/NRF2 axis and promotes triple-negative breast cancer progression.

ACOD1 is highly expressed in TNBC TAMs and is driven by TME signals, independent of the classical M2 polarization pathway, and promotes ITA binding to KEAP1, which inhibits the KEAP1-NRF2 interaction and thus activates NRF2-mediated antioxidant and ferroptosis resistance responses in TAMs, promoting TNBC progression.

Jie Yang, Xiyin Li, Xin Qu et al. · 1 citation

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.